Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
UBS
Citi
Julphar
US Army
Harvard Business School
Farmers Insurance
Merck
Deloitte

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,716,988

« Back to Dashboard

Summary for Patent: 5,716,988
Title: Pharmaceutically stable preparation of oxaliplatinum
Abstract:A pharmaceutically stable oxaliplatinum preparation for parenteral administration comprises an aqueous solution of oxaliplatinum, in a concentration of 1 to 5 mg/ml, and with a pH in the range of 4.5 to 6. The aqueous oxaliplatinum solution is advantageously provided as a ready-to-use preparation in a sealed container.
Inventor(s): Ibrahim; Houssam (Veyrier, CH), Mauvernay; Rolland-Yves (Lausanne, CH)
Assignee: Debiopharm S.A. (Lausanne, CH)
Application Number:08/776,240
Patent Claim Types:
see list of patent claims
Formulation; Device;

Drugs Protected by US Patent 5,716,988

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,716,988

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland2462/94Aug 08, 1994
PCT Information
PCT FiledAugust 07, 1995PCT Application Number:PCT/IB95/00614
PCT Publication Date:February 22, 1996PCT Publication Number: WO96/04904

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
AstraZeneca
Daiichi Sankyo
Medtronic
Colorcon
US Department of Justice
McKesson
Citi
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.